Complete Story
 

08/24/2020

Two New Launch Announcements by Incyte

TWO LAUNCH ANNOUNCEMENTS  BY INCYTE

 

Now approved, a new option for adult patients with relapsed or refractory Diffuse Large B-Cell Lymphoma:  Monjuvi

Pemazyre FDA Approved:  a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with  a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. 

Printer-Friendly Version